This page is translated by Google and can contain errors. Go back to English.

CTOS 2023: dedicated to improving outcomes for sarcoma patients

CTOS 2023: dedicated to improving outcomes for sarcoma patients

BRUSSELS - The Anticancer Fund, a non-profit organisation dedicated to advancing cancer research and treatment, is proud to announce its active participation in the annual Connective Tissue Oncology Society (CTOS) meeting, taking place in Dublin, Ireland. Two of the clinical trials we support, will present their findings at the conference.

The Connective Tissue Oncology Society (CTOS) is organising its annual meeting from 1-4 November in Dublin, Ireland. This meeting, considered the major scientific conference in the sarcoma world, brings together clinicians, researchers, funders, and patients from across the globe, all with a shared commitment to tackling these rare and difficult to treat cancers. The Anticancer Fund’s Director of Drug Repurposing, Pan Pantziarka, is representing our organisation at the event.

There are a number of things that makes CTOS of particular interest to the Anticancer Fund this year. At the forefront of our engagement are two of the clinical trials that we support, both of which will be presenting their findings at the conference.

We present two clinical trials

PropAngio, a window of opportunity trial assessing the impact of single-agent propranolol in angiosarcoma, will be reported as a poster presentation. Additionally, STRASS-2, a collaborative effort with the European Organisation for Research and Treatment of Cancer (EORTC), will be giving an update at the meeting. These trials highlight our focus on sarcomas, and our support for trials which are of no interest to pharmaceutical companies and other commercial interests.

Director of Clinical Research at the Anticancer Fund, Gauthier Bouche: “Our long-standing support to the sarcoma patients and researchers' community is starting to materialise. The results from PropAngio will inform us about what should happen next with propranolol in angiosarcoma. STRASS2 is being highlighted, while no results are yet available, because it is the poster child of what international collaboration in the interest of patients should look like”.

Fostering collaboration

Beyond our role in funding clinical trials, the Anticancer Fund is invested in fostering collaborative research efforts within the European community. Together with fellow osteosarcoma patients or parents of children with osteosarcoma, Pan Pantziarka will present a poster showcasing an international survey of bone sarcoma patients. In addition, several engaging side meetings are scheduled in Dublin. Of particular note is the participation of the Anticancer Fund in the EORTC Soft Tissue and Bone Sarcoma Group, aimed at discussing potential future projects and initiatives to further advance sarcoma research.

The Anticancer Fund is steadfast in its commitment to the sarcoma community, and CTOS 2023 serves as a beacon of expanding knowledge and enhancing collaboration in our mission to confront these challenging cancers. We invite all stakeholders in the field to join us in our efforts to make a meaningful difference in the lives of sarcoma patients worldwide.